A single-institutional retrospective observational study on evaluation of HER2 expression by immunohistochemical staining in unresectable advanced gastric cancer

A single-institutional retrospective observational study on evaluation of HER2 expression by immunohistochemical staining in unresectable advanced gastric cancer - HER_WEEKEND study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047115

Enrollment

180

Registered

2022-04-01

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cases in which HER2_IHC was performed when performing chemotherapy for unresectable advanced/recurrent gastric cancer. 2. Cases in which clinicopathological information can be collected at the time of HER2_IHC measurement.

Exclusion criteria

Exclusion criteria: 1. Cases in which HER2_IHC has not been performed. 2. Patients judged by the principal investigator to be inappropriate as research subjects.

Design outcomes

Primary

Measure	Time frame
HER2 positive rate: sample type (biopsy / surgical specimen) and test submission date (Weekday / Weekend)	—

Secondary

Measure	Time frame
1. HER2 positive rate among all study subjects 2. Comparison of HER2 positive rate by sample collection date (WD/WE) for different sample types (biopsy/surgical specimen) 3. Comparison of formalin fixation time by sample collection date (WD/WE) 4. Comparison of formalin fixation time by sample type (biopsy/surgical specimen) 5. Comparison of formalin fixation time in the sample type (biopsy/surgical specimen) according to the sample collection date (WD/WE) 6. Comparison of formalin fixation time and HER2 expression rate by sample type (biopsy/surgical specimen) 7. The difference in formalin fixation time (all population/sample type/sample collection date) 8. Comparison of treatment results by HER2 status (positive/negative) (overall survival from the start of chemotherapy, duration of response to trastuzumab combination therapy, and response rate)	—

Measure

Time frame

1. HER2 positive rate among all study subjects 2. Comparison of HER2 positive rate by sample collection date (WD/WE) for different sample types (biopsy/surgical specimen) 3. Comparison of formalin fixation time by sample collection date (WD/WE) 4. Comparison of formalin fixation time by sample type (biopsy/surgical specimen) 5. Comparison of formalin fixation time in the sample type (biopsy/surgical specimen) according to the sample collection date (WD/WE) 6. Comparison of formalin fixation time and HER2 expression rate by sample type (biopsy/surgical specimen) 7. The difference in formalin fixation time (all population/sample type/sample collection date) 8. Comparison of treatment results by HER2 status (positive/negative) (overall survival from the start of chemotherapy, duration of response to trastuzumab combination therapy, and response rate)

—

Countries

Japan

Contacts

Public ContactMichio Nakamura

Sapporo City General Hospital Department of Gastroenterology

michio.nakamura@doc.city.sapporo.jp011-726-2211

Outcome results